NEW YORK (GenomeWeb News) – Becton Dickinson today reported a 6 percent increase year over year in its revenues for fiscal first quarter 2014, while its profits were more than halved.

For the three months ended Dec. 31, 2013, BD posted revenues of $2.02 billon, compared to $1.90 billion a year ago, and beating the average analyst estimate of $1.98 billion. In a statement, the firm said that revenue growth came partly from favorable timing of orders in the BD Medical and BD Diagnostics segments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.